A nicotina é um alcalóide extraído da planta do tabaco e age como agonista em neurônios e outras células que expressam receptores nicotínicos. Essa substância é capaz de atravessar a barreira hematoencefálica e mimetizar os efeitos da acetilcolina endógena ao interagir com os diferentes subtipos de receptores. O hipocampo e o cerebelo são regiões encefálicas ricas em receptores nicotínicos como o alfa7 e o alfa42 que estão também envolvidos na progressão de doenças neurodegenerativas, como a doença de Alzheimer, e neuropsiquiátricas, como a esquizofrenia, ambas apresentando um contexto inflamatório. O lipopolissacarídeo (LPS) é um indutor inflamatório que age via receptor toll-4 (TLR-4) ativando, dentre outros, o fator de transcrição NF-capaB. Vários estudos têm demonstrado tanto in vitro quanto in vivo que a exposição crônica à nicotina inibe a resposta imune. Uma vez que o fator de transcrição NF-capaB regula a expressão gênica de diversos fatores que medeiam a plasticidade e o desenvolvimento neuronal e inflamação, nosso objetivo foi avaliar os efeitos da nicotina crônica sobre a via de sinalização induzida pelo LPS. Sendo assim, avaliou-se a translocação nuclear do NF-capaB, a expressão de indutores inflamatórios (TNF, IL-1 e iNOS) e também do receptor TLR-4 tanto no hipocampo quanto no cerebelo. Além disso, foram determinados os níveis plasmáticos das citocinas TNF, IL-1, MIP-1alfa, CINC2alfa/. Nossos resultados mostram que, perifericamente, o LPS induziu a produção das citocinas plasmáticas, mas a nicotina não foi capaz de reverter seus efeitos. Já no cerebelo e no hipocampo, a nicotina crônica (0,1 e 1,0 mg/kg) interferiu significativamente na translocação do NF-capaB induzida pelo LPS, levando inclusive a um bloqueio importante da expressão do mRNA de TNF, IL-1, iNOS no hipocampo, e de IL-1 no cerebelo. Ademais, no hipocampo, a nicotina também interferiu na expressão do receptor TLR-4. A mecamilamina, antagonista heteromérico não-seletivo não foi capaz de reverter os efeitos da nicotina sobre o NF-capaB no hipocampo, mas o fez no cerebelo. Já o antagonista seletivo de receptor alfa 7, metililaconitina, bloqueou a ação da nicotina no hipocampo. / Nicotine is an alkaloid extracted from Tobacco plants, and it acts as an agonist in neurons and other cells that express nicotinic receptors. This substance crosses the blood brain barrier and mimics endogenous acetylcholine in interacting with various receptor subtypes. The hippocampus and cerebellum are brain regions rich in nicotinic receptors including 7, 42 and other subtypes, involved in neurodegenerative and neuropsychiatric disorders, including Alzheimer disease and schizophrenia, respectively, in a neuroinflammatory context. The lipopolysaccharide (LPS) is a known inflammatory inducer that exerts its effects through the Toll-like receptor 4 (TLR-4) and activates the transcription factor NF-capaB. In the present work, we evaluate the effects of chronic nicotine on the nuclear translocation of NF-capaB, on the expression of NF-capaB regulated inflammatory inducers (TNF, IL-1 and iNOS) and on the LPS-induced TLR4 mRNA expression in response to chronic nicotine treatment in hippocampus and cerebellum. In addition, we accessed the production of peripheral cytokines (TNF, IL-1, MIP-1, CINC 2/). Our results demonstrate that LPS induced the production of peripheral cytokines but nicotine treatment did not interfere in their plasma levels. However, in cerebellum and hippocampus, chronic nicotine 1.0 and 0.1 mg/kg interfered in the LPS-induced NF-capaB leading to a deficient mRNA expression of its related genes TNF, IL-1 and iNOS in hippocampus and of IL-1, in cerebellum. Chronic nicotine (0.1 mg/kg, s.c.) significantly interfered in the TLR4 mRNA expression in LPS-challenged animal group in hippocampus. The non-selective heteromeric antagonist mecamylamine (1.0 mg/kg s.c.) reverted the nicotine effects over NF-capaB nuclear translocation in cerebellum, but not in hippocampus. On the other hand, the 7 antagonist methyllycaconitine (MLA) (5.0 mg/kg i.p.) reverted the nicotine effects over NF-capaB in hippocampus but not in cerebellum. Nicotine prevents LPS effects, both in cerebellum and hippocampus, once it reduced significantly the nuclear translocation of NF-capaB and the expression of related pro-inflammatory cytokines. Besides, the nicotinic effects seem to be mainly mediated by heteromeric receptors in cerebellum and through 7 receptors in hippocampus.

Neuronal nicotinic acetylcholine receptors (nAChRs) are ligand-gated cation channels that most notably influence dopamine (DA) release. In this thesis, I examine the role of nAChRs in mediating DA-related behaviors such as movement and drug dependence. To accomplish this, I utilized a “gain-offunction” knock-in mouse (the Leu9’Ala line) containing agonist-hypersensitive α4* nAChRs (* indicates other nAChR subunits in addition to α4 are within the receptor complex) that renders receptors 50-fold more sensitive to nicotine and acetylcholine than wild-type (WT) receptors. I found that DHβE, a selective antagonist for α4β2* nAChRs, induced reversible and robust motor dysfunction characterized by hypolocomotion, akinesia, catalepsy, tremor, and clasping in Leu9’Ala but not WT mice. Reversal of the phenotype was achieved by targeting dopamine signaling. Blockade of mutant α4* nAChRs elicited activation of brain regions in the basal ganglia including dorsal striatum and substantia nigra pars reticulata indicated by c-Fos immunoreactivity. These data indicate that blocking α4* nAChRs in Leu9’Ala mice activates the indirect motor pathway resulting in a motor deficit. We also determined that α4* nAChRs involved in motor behaviors did not contain the α6 subunit, a nAChR subunit highly expressed in DAergic neurons suggesting that different nAChR subtypes modulating striatal DA release have separate functions in motor output. Conditioned place aversion and hypolocomotion, behaviors elicited during nicotine withdrawal, were also induced by DHβE in nicotine-naïve Leu9’Ala but not WT mice. Together these data suggest that DHβE globally reduces DA release in the CNS. In a separate project, I determined that α4* and α6* nAChRs modulate drug-induced hypnosis. Activation of nAChRs increased sensitivity to ketamine-induced hypnosis; whereas antagonizing nAChRs had the opposite effect. Additionally, α4 knockout (KO) mice were less sensitive to the hypnotic effects of ketamine, but α6 KO were more sensitive. High doses of ethanol induce an anesthesia-like state characterized by immobility, analgesia, and hypnosis. Testing the effects of ethanol hypnosis in α4 KO revealed that α4* nAChR do not play a large role in the acute effects of ethanol-induced hypnosis, but are involved in tolerance to this ethanol-induced behavior. The mechanisms of anesthetic-induced hypnosis are still largely unclear, despite the wide use of anesthesia. Future work on these receptors and their involvement in the anesthetic response will help to define a mechanism for hypnosis and improve the use of anesthetic drugs.

Recently, the medial habenula-interpeduncular (MHb-IPN) axis has been hypothesized to modulate anxiety although neuronal populations and molecular mechanisms regulating affective behaviors in this circuit are unknown. Here we show that MHb cholinergic neuron activity directly regulates anxiety-like behavior. Optogenetic silencing of MHb cholinergic IPN inputs reduced anxiety-like behavior in mice. MHb cholinergic neurons are unique in that they robustly express neuronal nicotinic acetylcholine receptors (nAChRs), although their role as autoreceptors in these neurons has not been described. nAChRs are ligand-gated cation channels that are activated by the excitatory neurotransmitter, acetylcholine (ACh), as well as nicotine, the addictive component of tobacco smoke. We expressed novel nAChR subunits that render nAChRs hypersensitive to ACh, ACh detectors, selectively in MHb cholinergic neurons of adult mice. Mice expressing these ACh detectors exhibited increased baseline anxiety-like behavior that was alleviated by blocking the mutant receptors. Under stressful conditions, such as during nicotine withdrawal, nAChRs were functionally upregulated in MHb cholinergic neurons mediating an increase in anxiety-like behavior. Together, these data indicate that MHb cholinergic neurons regulate anxiety via signaling through nicotinic autoreceptors and point toward nAChRs in MHb as molecular targets for novel anxiolytic therapeutics.

Nicotine dependence is hypothesized to be due to neuroadaptations that ultimately drive compulsive nicotine use. The studies in this thesis aim to understand how the “upregulation” of nicotinic acetylcholine receptors (nAChRs) caused by chronic exposure to nicotine contributes to nicotine reward and nicotine withdrawal. Previous studies have shown that chronic nicotine induces upregulation of nAChRs containing the α4 subunit (α4* nAChR) within the Ventral Tegmental Area (VTA), a brain region critical for the rewarding properties of all illicit drugs. Curiously, α4* nAChR upregulation occurs specifically in the inhibitory GABAergic neuronal subpopulation of the VTA. To determine if increased expression and activation of α4* nAChRs in VTA GABAergic neurons contributes to nicotine dependence behaviors, I devised a viral-mediated, Creregulated gene expression system that selectively expressed α4 nAChR subunits containing a “gain-of-function” point mutation (a leucine mutated to a serine residue at the TM2 9´ position: Leu9´Ser) in VTA GABAergic neurons of adult mice. Sub-reward doses of nicotine were sufficient to activate VTA GABAergic neurons in mice expressing Leu9´Ser α4 nAChR subunits in VTA GABAergic neurons (Gad2VTA: Leu9´Ser mice) and exhibited acute hypolocomotion upon initial injection of low doses of nicotine that developed tolerance with subsequent nicotine exposures compared to control animals. In the conditioned place preference procedure, nicotine was sufficient to condition a significant place preference in Gad2VTA: Leu9´Ser mice at low nicotine doses that failed to condition control animals. I conclude from these data that upregulating α4* nAChRs on VTA GABAergic neurons increases sensitivity to nicotine reward. In a separate study testing the hypothesis that overexpression of Leu9´Ser α4* nAChRs in VTA GABAergic neurons disrupts baseline behavior and promotes anxiety-like behaviors, I found that overexpressing Leu9´Ser α4* nAChRs in VTA GABAergic neurons had a minimal effect on unconditioned anxiety-like behaviors. Drug naïve Gad2VTA: Leu9´Ser and control mice failed to exhibit any behavioral differences in the open-field, marble burying test and elevated plus maze compared to control. Together, these data indicate that overexpression of the “gain-of-function” α4* nAChRs in VTA GABAergic neurons contributes to reward sensitivity without increasing susceptibility to nicotine withdrawal symptoms. My data indicates that nAChRs expressed in VTA GABAergic neurons may be a suitable target for the development of better smoking cessation aids.